Serving hundreds of leading biopharmaceutical companies globally:

Generated: December 12, 2018

DrugPatentWatch Database Preview

Details for Patent: 10,004,717

« Back to Dashboard

Which drugs does patent 10,004,717 protect, and when does it expire?

Patent 10,004,717 protects QBREXZA and is included in one NDA.

This patent has sixteen patent family members in eleven countries.

Summary for Patent: 10,004,717

Title:	Glycopyrrolate salts
Abstract:	Salts of glycopyrrolate, including solid forms and formulations such as topicals thereof, are disclosed. Methods of making glycopyrrolate salts, including formulations such as topicals thereof, and methods of treating hyperhidrosis with salts of glycopyrrolate, and formulations such as topicals thereof, are disclosed.
Inventor(s):	Statler; John Allan (Redwood City, CA), Shaw; Anthony Adrian (North Vancouver, CA), Imbert; Delphine Caroline (Cupertino, CA), Nelson; Jennifer Leigh (Kokomo, IN), Andres; Patricia (West Lafayette, IN), McQueen; Lisa Lynn (West Lafayette, IN), Boerrigter; Stephan Xander Mattheus (West Lafayette, IN), Selbo; Jon Gordon (West Lafayette, IN), Andres; Mark Christopher (West Lafayette, IN)
Assignee:	DERMIRA, INC. (Menlo Park, CA)
Application Number:	15/438,636
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 10,004,717

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Dermira Inc	QBREXZA	glycopyrronium tosylate	CLOTH;TOPICAL	210361-001	Jun 28, 2018		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y			TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 10,004,717

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014223172	➤ Sign Up
Australia	2016269524	➤ Sign Up
Canada	2902795	➤ Sign Up
China	105026369	➤ Sign Up
European Patent Office	2961734	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant

QuintilesIMS

Moodys

Deloitte

Citi

UBS

Medtronic

US Department of Justice

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.